18:37:17 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-11-21 15-10 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-24 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2024-05-23 Årsstämma 2024
2024-02-29 Extra Bolagsstämma 2024
2024-02-22 Bokslutskommuniké 2023
2023-11-23 Kvartalsrapport 2023-Q3
2023-11-14 Extra Bolagsstämma 2023
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-29 Kvartalsrapport 2023-Q1
2023-05-26 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2023-05-25 Årsstämma 2023
2023-02-23 Bokslutskommuniké 2022
2023-02-10 Extra Bolagsstämma 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-25 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2022-05-24 Kvartalsrapport 2022-Q1
2022-05-24 Årsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-11-25 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-28 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2021-05-27 Årsstämma 2021
2021-05-27 Kvartalsrapport 2021-Q1
2021-02-25 Bokslutskommuniké 2020
2020-11-26 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-07-02 Extra Bolagsstämma 2020
2020-05-29 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2020-05-28 Kvartalsrapport 2020-Q1
2020-05-28 Årsstämma 2020
2020-02-28 Bokslutskommuniké 2019
2019-11-22 Kvartalsrapport 2019-Q3
2019-08-23 Kvartalsrapport 2019-Q2
2019-05-29 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2019-05-28 Årsstämma 2019
2019-05-17 Kvartalsrapport 2019-Q1
2019-04-02 Extra Bolagsstämma 2019
2019-03-01 Bokslutskommuniké 2018
2018-11-23 Kvartalsrapport 2018-Q3
2018-08-24 Kvartalsrapport 2018-Q2
2018-05-29 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2018-05-28 Årsstämma 2018
2018-05-18 Kvartalsrapport 2018-Q1
2018-02-15 Bokslutskommuniké 2017

Beskrivning

LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
2cureX är verksamt inom cancerbehandling. Idag tillhandahåller bolaget olika verktyg som används av läkare vid behandlingar för att mäta effekt och resistens hos cancerläkemedel på patientens egna cancerceller. Målet är att förkorta behandlingsperioden samt hitta rätt individuell behandling. Störst verksamhet innehas på den europeiska marknaden. Huvudkontoret ligger i Köpenhamn.
2023-02-23 08:30:00

2cureX AB (“2cureX”) hereby publishes the interim report for the fourth quarter and full year of 2022. The interim report is available as an attached document as well as on the company’s website (https://www.2curex.com). A short summary of the report follows below.

CEO Fernando Andreu comments:

“We finished a very successful 2022 and are proud to look back at a year where we met our goal of having IndiTreat present in 20 countries, with a total population of approximately 385M people. This - together with the expansion of our product portfolio - has considerably advanced our lead in the race for the Functional Drug Sensitivity Testing (f-DST) market.

The fourth quarter of 2022 was our strongest quarter to date, and in this quarter we enrolled as many as 9 additional hospitals to the IGNITE program compared to our revised goal of 5 hospitals. Once again we received reaffirmation that our IGNITE program is a good path to expose the benefits of IndiTreat to potential customers and we will continue our efforts on driving this forward.

Building on the positive developments of 2022 we have set ambitious goals for 2023, where we will focus our efforts and activities on penetrating the incipient European market as well as pushing forward on expanding the adoption of the f-DST technology.”

FINANCIAL HIGHLIGHTS
The financial development is in line with our plans and expectations, and with a cash position of SEK 45 MSEK at the end of 2022, our capital resources can support the current activities and growth plans.”

Full year of 2022 (2022-01-01 until 2022-12-31) – the group

Net turnover for the period was 90 KSEK (0 KSEK).
Other operating income was 3 279 KSEK (7 391 KSEK)
The result before tax was -29 770 KSEK (-22 479 KSEK)
The result per share* was -1.69 SEK (-1.15 SEK)
The solidity** was 90 % (94 %).
The cash and bank were 44 894 KSEK (72 942 KSEK).

*Earnings per share: Profit for the period divided by the average number of shares. Average number of shares in 2022: 17 580 961 shares. Total number of shares in 2cureX AB on December 31st, 2022: 17 602 916 shares.
**Equity ratio: Shareholder’s equity divided by total capital.

Significant events during the fourth quarter 2022

October:

2cureX celebrates co-inventor of patents awarded Nobel Prize in Chemistry

Independent market survey shows great demand for 2cureX product portfolio

November:

2cureX hosted a deep dive session of its operational and commercial strategy

2curex discloses status of 2022 plans, goals for 2023 and its estimates of potential market development in the coming years

2cureX publishes interim report for the third quarter 2022 and presents in live webcast

December:

2curex announces reaching the 2022 geographic rollout goal of 20 countries

Significant events after the period

January:

2curex announces final results regarding 2022 goals

2curex sends notice to attend the extraordinary general meeting for new board member

For more information about 2cureX:

Fernando Andreu, Chief Executive Officer
E-mail: fa@2curex.com
Telephone: +45 2279 5399
www.2curex.com

Kenneth Graabek Johansen, Chief Financial Officer
E-mail: kgj@2curex.com
Telephone: +45 2349 0227
www.2curex.com